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ABSTRACT
Introduction: Skeletal muscle impairment is an
important feature of chronic obstructive pulmonary
disease (COPD). Renin–angiotensin system activity
influences muscle phenotype, so we wished to
investigate whether it affects the response to
pulmonary rehabilitation.
Methods: Two studies are described; in the first, the
response of 168 COPD patients (mean forced
expiratory volume in one second 51.9% predicted) to
pulmonary rehabilitation was compared between
different ACE insertion/deletion polymorphism
genotypes. In a second, independent COPD cohort
(n=373), baseline characteristics and response to
pulmonary rehabilitation were compared between
COPD patients who were or were not taking ACE
inhibitors or angiotensin receptor antagonists (ARB).
Results: In study 1, the incremental shuttle walk
distance improved to a similar extent in all three
genotypes; DD/ID/II (n=48/91/29) 69(67)m, 61 (76)m
and 78 (78)m, respectively, (p>0.05). In study 2, fat
free mass index was higher in those on ACE-I/ARB
(n=130) than those who were not (n=243), 17.8 (16.0,
19.8) kg m−2 vs 16.5 (14.9, 18.4) kg/m2 (p<0.001).
However change in fat free mass, walking distance or
quality of life in response to pulmonary rehabilitation
did not differ between groups.
Conclusions: While these data support a positive
association of ACE-I/ARB treatment and body
composition in COPD, neither treatment to reduce ACE
activity nor ACE (I/D) genotype influence response to
pulmonary rehabilitation.
BACKGROUND
Skeletal muscle impairment is a common
and important feature of chronic obstructive
pulmonary disease (COPD), occurring in
about one-third of patients irrespective of
the severity of their airﬂow obstruction.1–3 It
is associated with reduced exercise capacity,4
as well as impaired quality of life,5 and quad-
riceps weakness has been shown to predict
mortality in COPD independent of lung
function.6 Physical inactivity is clearly a key
driver of muscle weakness in COPD,3 7 8
although other factors, for example inﬂam-
mation, hypoxia and hormonal factors, as
well as genetic predisposition, may be
important.5 9–11 Moreover, there is strong evi-
dence that pulmonary rehabilitation (PR), a
programme of supervised exercise and edu-
cation, can produce signiﬁcant improve-
ments in quality of life, muscle strength and
endurance, as well as exercise capacity, in
patients with COPD.12 13
The circulating (endocrine) renin–angio-
tensin system (RAS) plays an important role in
circulatory homeostasis, degrading vasodilator
bradykinin and synthesising vasoconstrictor
(and renal sodium-retaining) angiotensin II.
However, local RAS also exists in diverse
tissues14 including skeletal muscle.15 The pres-
ence (insertion, I) rather than the absence
(deletion, D) of a 287 base pair sequence in
intron 16 of the human ACE inhibitors gene is
associated with lower tissue16 17 and circulating
ACE activity.18 19 In turn, an extensive litera-
ture supports an association between ACE
genotype and physical performance, the
I allele being associated with endurance per-
formance, and the D with power/sprint per-
formance.19 20 The ACE (I/D) polymorphism,
as well as polymorphisms of genes for bradyki-
nin type 2 (BK(2)R) and vitamin D receptors,
have been shown to inﬂuence strength and
body composition in COPD.9–11 Furthermore,
ACE-I use in patients with hypertension has
KEY MESSAGES
▸ Treatment with an ACE-I/angiotensin receptor
blocker is associated with higher fat free mass
in people with COPD.
▸ Neither treatment with ACE-I/angiotensin
receptor blocker nor ACE (I/D) polymorphism
appear to influence response to pulmonary
rehabilitation.
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Chronic obstructive pulmonary disease
been associated with preservation of quadriceps strength
and walking speed compared to those on other medica-
tions or controls.21
Given these data, we wished to establish whether
factors known to affect RAS activity might inﬂuence
response to PR in patients with COPD. We investigated
this by conducting two studies. The ﬁrst explored the
impact of the ACE (I/D) polymorphism on responses to
PR in patients with COPD. The second, in a separate
cohort, investigated the effects of concomitant ACE-I or
angiotensin II receptor blocker (ARB) use in patients
with COPD, testing the hypothesis that this would be
associated with preserved fat free mass (FFM) and an
enhanced response to PR.
METHODS
Study 1, investigating the effect of ACE genotype, was
approved by the Ethics Committee of King’s College
Hospital (05/Q0703/134) and funded by The British
Lung Foundation and started in 2004. Participants pro-
vided written informed consent. The study was retro-
spective and involved contacting patients with a clinical
diagnosis of COPD who had completed a PR pro-
gramme at King’s College or Royal Brompton and
Hareﬁeld Hospitals. The PR programmes consisted of
an 8 week course of aerobic and strength activities with
two supervised and one or more home sessions per
week. The initial exercise prescription was based on the
outcome of their baseline incremental shuttle walk test
distance (ISWD),22 and workloads were increased
through the programme as tolerated. Programmes were
multidisciplinary with an educational component cover-
ing issues including exercise, medication use, diet and
coping strategies. Patients with COPD who attended at
least 75% of their scheduled rehabilitation sessions and
had ISWD measured pre-rehabilitation and immediately
post-rehabilitation were invited to take part. Either a
blood sample or a mouth swab was obtained from each
patient to collect cells from which the PCR was used to
determine ACE genotype.11 None of the patients or clin-
ical research staff involved in the study knew the geno-
type of participants until after the phenotypic outcomes
database had been ﬁnalised.
The association of ACE genotype with baseline
characteristics and response to PR was assessed across all
three genotypes by ANOVA and also between those with
or without the D or I allele by unpaired t-test. The
primary end point was change in ISWD immediately
after PR. A p value of <0.05 was taken as signiﬁcant and
StatView 4.0 used for analysis.
In study 2, routinely collected data from a different
cohort of patients with COPD who had been referred
for a course of PR at Hareﬁeld Hospital between 2009
and 2011 were used. The Ethics Committee of Royal
Brompton Hospital has determined that ethical approval
is not required for the retrospective analysis of routinely
collected clinical data. The primary outcome was differ-
ences in the response to PR of ISWD between patients
who were or were not on an ACE-I or ARB (determined
by patient self-report). Additional outcomes were fat free
mass index (FFMI) determined by bioelectrical imped-
ance analysis using a disease-speciﬁc regression equa-
tion,23 and the chronic respiratory disease questionnaire
(CRQ)24 and the COPD assessment test score
(CAT).13 25 Data from 72 of the patients in study 2 were
included in a previous publication.13
RESULTS
Study 1: effect of ACE genotype on response to PR
Data were available for 168 individuals who had partici-
pated in PR; 92 (53.8%) women, forced expiratory
volume in one second (FEV1) 51.9 (22.7)% predicted.
ACE genotypes were DD 48 (28%); ID 91 (53%); II 29
(19%) (table 1). There was no signiﬁcant difference in
patients’ characteristics by ACE genotype either across
all three possible genotypes (ﬁgure 1) or comparing
those with or without an I or a D allele. Exercise capacity
improved following PR in the whole study population
with a mean increase in ISWD of 67.5(74.7)m and for
each genotype (all p<0.0001), but the response did not
differ signiﬁcantly between genotypes (ANOVA, p=0.5).
Study 2: effect of ACE-I or ARB on response to PR
Baseline data from 373 consecutive COPD patients
(213M:160F; mean age 68.3; median FEV1 41% predicted)
referred to an outpatient PR programme were analysed
Table 1 Study 1: patient characteristics for whole group and separated by ACE genotype
All
n=168
DD
n=48 (28%)
ID
n=91 (53%)
II
n=29 (19%)
Age 68.7 (9.0) 69.2 (10.4) 67.8 (8.8) 71.0 (6.9)
Gender (n(%) female) 92 (54.8) 23 (47.9) 52 (57.1) 15 (51.7)
FEV1 (% predicted) 51.9 (22.7) 50.4 (22.3) 52.8 (24.4) 50.1 (18.7)
FEV1/FVC (%) 48.1 (17.6) 48.0 (17.7) 48.7 (19.3) 46.2 (13.2)
ISWD baseline (m) 251.4 (149.8) 261.7 (184.0) 253.0 (140.2) 223.4 (103.9)
ISWD end (m) 318.9 (170.6) 331.0 (200.0) 313.6 (165.3) 301.7 (109.4)
ΔISWD (m) 67.5 (74.7) 69.4 (66.6) 60.6 (76.2) 78.3 (78.2)
ΔISWD (%) 43.3 (66.7) 45.6 (76.9) 36.0 (53.2) 59.2 (84.5)
Values are mean (SD). All p>0.05 ANOVA across genotypes.
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ISWD, incremental shuttle walk test distance.
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(table 2). Of these, 130 reported taking either an ACE-I
(n=82), ARB (n=45) or both (n=3). The groups had
similar gender distribution and long-term oral corticoster-
oid use. Patients on ACE-I or ARB were older, had less
severe airﬂow obstruction but similar values for ISWD,
CRQ, Medical Research Council dyspnoea score (MRC)
and CAT. However, the patients receiving ACE-I or ARB
had signiﬁcantly higher FFM and FFMI 17.8 kg/m2 (16.0,
19.8) versus 16.5 kg/m2 (14.9, 18.4) (p<0.0001 when
adjusted for difference in FEV1 and age).
A total of 255 patients completed the PR programme,
76 (30%) of whom were taking an ACE-I/ARB.
Responses did not differ between those who were or
were not on an ACE-I or ARB (table 3), with improve-
ments in ISWD and CRQ exceeding the minimum clin-
ically important difference.
DISCUSSION
The present data suggest that the beneﬁcial response to
PR in COPD patients was not strongly inﬂuenced by
their ACE (I/D) genotype, or by pharmacological RAS
antagonism. However, long-term use of an ACE-I/ARB
was associated with relatively preserved FFM in patients
referred for PR.
Rationale for studying the RAS in COPD
In patients with COPD, the quadriceps muscle displays
muscle ﬁbre atrophy and a shift away from an endurance
phenotype, with a reduced proportion of type I slow
twitch, fatigue-resistant ﬁbres together with reduced
capillarity and oxidative enzymes.26–30 The RAS and thus
ACE inhibitors and functional ACE gene polymorphisms
have the potential to inﬂuence these processes through
a number of mechanisms. These include effects on
muscle atrophy/hypertrophy signalling, ﬁbre shift, sys-
temic inﬂammation and remodelling.31 Angiotensin II
opposes the action of the insulin-like growth factor
(IGF-1) system activating the ubiquitin-proteasome pro-
teolytic pathway via IGF-1 and via NF-kB,32 33 and IGF-1
levels are reduced in the quadriceps of COPD patients
Figure 1 Plot of change in
incremental shuttle walk test
following pulmonary rehabilitation
according to ACE (insertion/
deletion) polymorphism. A total of
168 COPD patients took part, DD
48 (28%); ID 91 (53%); II 29
(19%). The horizontal line
represents median value. Boxes
represent 25th/75th centiles;
whiskers 10th/90th centiles
(ANOVA, p=0.5).
Table 2 Study 2: baseline patient characteristics separated by whether patients were or were not taking an ACE-I or ARB.
ARB or ACE-I
n=130
No ARB or ACE-I
n=243 p Value
Age (years) 71 (64, 78) 67.6 (9.8) 0.004
FEV1 (% predicted) 44.5 (32.3, 60.8) 39.0 (26.0, 58.5) 0.007
FFM (kg) 51.1 (11.2) 45.5 (40.1, 52.0) <0.001
FFMI (kg/m2) 17.8 (16.0, 19.8) 16.5 (14.9, 18.4) <0.001
ISWD (m) 140 (60, 250) 160 (80, 280) 0.10
CRQ 71.5 (55.8, 91.0) 68.0 (56.0, 87.0) 0.45
MRC dyspnoea score 4 (3, 5) 4 (3, 5) 0.79
CAT score 23.0 (8.0) 22.0 (7.0) 0.76
p Values are for unpaired t-tests. Data are presented as median (25th, 75th centiles) or (SD).
ACE-I, ACE inhibitor; ARB, AT II receptor antagonist; CAT, COPD assessment test score; CRQ, chronic respiratory disease questionnaire;
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FFM, fat free mass; FFMI, fat free mass index; ISWD, incremental
shuttle walk test distance.
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in the stable state compared to healthy controls.34
Increases in exercise capacity and ﬁbre size in COPD
patients undergoing PR are associated with upregulation
of IGF-1 and its splice variant mechano-growth factor
(MGF).35
The I allele of the ACE gene polymorphism is asso-
ciated with a higher proportion of type I ﬁbres,36 and
there is evidence that ACE inhibitors and AT II receptor
antagonists interact with peroxisome proliferator-
activated receptors (PPARs)37 38 which are major regula-
tors of cell metabolism mediating type II (anaerobic) to
type I (aerobic) ﬁbre shift and regulate mitochondrial
activity as well as muscle oxidative status.39–41 This is
potentially of particular relevance in COPD given that
PPAR-delta protein content is decreased in the skeletal
muscle of these patients.42 The DD genotype has also
been associated with systemic inﬂammation in COPD.43
In stable COPD patients, the deletion allele (D) of the
ACE gene polymorphism has been associated with
increased quadriceps strength, in contrast to age-
matched healthy controls where this relationship was
not observed.11
Effect of ACE inhibition in COPD
In the present cross-sectional study, patients taking an
ACE-I/ARB did have relatively preserved FFM, though
this was not associated with differences in exercise cap-
acity. Patients had not been randomly allocated to treat-
ment so these data need to be treated with caution, but
they are consistent with a beneﬁcial effect of reduced
ACE activity on body composition.44
In keeping with this, in healthy older people the use
of ACE-I as a treatment for hypertension is associated
with relative preservation of lower limb muscle mass,45
and with a reduced rate of loss of knee extensor
strength21 compared to patients using other antihyper-
tensives or to those not treated for hypertension. The
ACE-I perindopril has been shown to increase 6 min
walk distance in older people.46 A small number of
studies have investigated the effects of RAS inhibition in
COPD patients.47–50 In one study captopril improved
pulmonary haemodynamics during exercise in patients
with the ID or II genotype47 though other studies have
not found similar effects.51 52 A double-blind, placebo-
controlled study by Di Marco et al evaluated the effects
of 4 weeks treatment with enalapril on exercise perform-
ance in 21 COPD patients ﬁnding that it increased peak
work rate in the treatment group compared to placebo,
an effect not signiﬁcantly modiﬁed by ACE genotype.53
A randomised controlled trial of fosinopril in 80 patients
with COPD selected for quadriceps weakness found no
beneﬁt,49 and enalapril did not enhance the effect of
PR on improvements in exercise performance in
COPD.50 Of note, these two studies excluded people
with a clinical indication for an ACE-I who, by deﬁnition,
are the subject of the present paper.
Epidemiological data suggest a survival beneﬁt in
patients with COPD who are on an ACE-I.54 55 However,
in the present study, treatment with an ACE-I was not
associated with greater strength or exercise capacity.
Interestingly, the patients on ACE-I/ARB had less severe
airﬂow obstruction but similar health status and dys-
pnoea. It is therefore possible that comorbidities such as
cardiac impairment were contributing to their overall
symptom burden and exercise limitation which might
have had an effect on response to PR.
We found no association of the ACE(I/D) genotype
with response to PR. This contrasts with Gosker et al who
found, in a study of 95 COPD patients undergoing PR,
that the improvement in peak VO2 during cycle ergome-
try was signiﬁcantly less in patients with the DD geno-
type.56 However in that study, those with an I allele had
a lower exercise capacity initially so may have been more
detrained. The difference could also be due to the test
modalities employed in the two studies (walking vs
cycling) or a regression to the mean effect.
Critique of methods
Functional exercise capacity is an integrative end point
subject to respiratory, cardiac, skeletal muscle and
motivational limitation, so the absence of an apparent
effect of ACE genotype or ACE-I on response does not
preclude the possibility of some physiological impact
which might have been more apparent with a more con-
trolled exercise end point such as metabolic parameters
at a particular workload. Since the RAS is active at a
number of levels, it may be that impacts on muscle
strength, muscle endurance and the systemic and pul-
monary vascular system may have opposing effects which
a walking test cannot separate.
This paper addresses the question of whether either
the genotype or treatment with drugs that inﬂuence the
ACE system has an effect, in clinical practice, on
outcome measures accepted as clinically relevant in
international guidelines for PR—health status and exer-
cise capacity assessed using a walking test.13 There is of
course ongoing debate about the different information
conveyed by laboratory and ﬁeld tests of exercise per-
formance as well as walking versus cycling, but there is
certainly no reason to ascribe greater clinical relevance
to VO2 max, etc than to performance on a ﬁeld walking
Table 3 Study 2: response to pulmonary rehabilitation in
COPD patients who were or were not taking an ACE-I or
ARB.
ARB or ACE-I
n=76
No ARB or ACE-I
n=179 p value
ΔFFM (kg) −1.7 (2.7) 1.8 (1.4) 0.21
ΔISWD (m) 104 (21) 63 (15) 0.13
ΔCRQ 16.2 (3.8) 17.7 (2.5) 0.75
ACE-I, ACE inhibitors; ARB, AT II receptor antagonist; FFM, fat
free mass; ISWD, incremental shuttle walk test distance; CRQ,
chronic respiratory disease questionnaire.
All p>0.05. Data are presented as mean (SD).
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test when considering daily physical activity or patient-
relevant outcomes.
Patient recruitment for the genotyping study was retro-
spective, so it is conceivable that some survival or other
bias was in operation. Genotype data were not available
for the cohort in study 2, so it is not possible to comment
on possible interactions between genotype and treatment
with ACE-I/ARB. It is possible that disease processes for
which RAS antagonists were prescribed were themselves
associated with differences in body composition. All parti-
cipants were taking part in clinical PR programmes and
data were entered prospectively, but because they were
clinical programmes the full range of possible pheno-
types were not recorded as might have been the case in a
prospective study, such as exacerbation frequency and
multimorbidities, as well as more detailed lung function
parameters or gas transfer.57
Patient treatments were based on self-report, so it is
possible that an effect of ACE-I or ARB was underesti-
mated because of poor compliance with medication.
CONCLUSIONS
Although treatment with an ACE-I/ARB was associated
with a higher FFM in patients with COPD, neither the
ACE (I/D) polymorphism nor treatment with an ACE/
ARB appear to inﬂuence response to PR despite previ-
ous data showing an association with quadriceps
strength. Although trial data do not support a beneﬁcial
effect from the addition of an ACE-I in COPD patients
who do not have a conventional clinical indication,49 50
the present data do not suggest that there is any advan-
tage to avoiding or stopping ACE-I in COPD patients in
whom they are indicated.
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